Modeling Prostate Cancer by Conditional Gene Targeting
通过条件基因靶向模拟前列腺癌
基本信息
- 批准号:6456082
- 负责人:
- 金额:$ 24.79万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2002
- 资助国家:美国
- 起止时间:2002-07-01 至 2007-06-30
- 项目状态:已结题
- 来源:
- 关键词:androgens angiogenesis apoptosis carcinogenesis cell cycle cell cycle proteins cell proliferation chromosome aberrations disease /disorder model enzyme inhibitors gene expression gene mutation gene targeting genetic models genetically modified animals immunocytochemistry laboratory mouse male castration metastasis model design /development neoplasm /cancer genetics oncogenes polymerase chain reaction prostate neoplasms prostate specific antigen protein kinase protooncogene
项目摘要
Most current transgenic mouse models of prostate cancer suffer from the drawback that the initiating oncogene (the SV40 T antigen) has no known role in the pathogenesis of the human disease. Thus it is critical to generate an improved murine model of prostate cancer that is based on the genetic lesions commonly observed in human prostate carcinoma. Two of the most common chromosomal aberrations observed in prostate carcinoma cells include loss of sequences from the short arm of chromosome 8 and gain of sequences on its long arm. A strong candidate for a tumor suppressor located at 8p21 is Nkx3.1, a homeobox- containing protein whose expression is lost in many prostate tumors and prostatic intraepithelial neoplasia (PIN) lesions. We have used Cre/loxP-mediated recombination to generate mice with deletion of Nkx3.1 in the adult prostate. These mice develop preinvasive PIN lesions. The Myc oncogene maps to 8q24, and is the target for amplification in many prostate tumors. Overrepresentation of Myc gradually increases in PIN lesions, primary carcinomas and metastases, indicating that Myc overexpression is associated with tumor progression. Intriguingly, gain of 8q24 is often accompanied by loss of 8p21 in prostate carcinomas, and concurrent loss of 8p and gain of 8q is associated with poor patient prognosis. The overall goal of this proposal is to generate and characterize mice with conditional loss of Nkx3.1 and gain of Myc in the adult prostate. We hypothesize that cooperation between loss of Nkx3.1 and gain of Myc will result in the progression of PIN lesions to invasive carcinoma and ultimately metastatic disease. The following Specific Aims are proposed: 1) To generate and characterize transgenic mice that overexpress Myc upon Cre- mediated recombination in the prostate. 2) To generate and characterize mice with concurrent loss of Nkx3.1 and overexpression of Myc in the prostate. 3) To examine the genetic pathways altered in prostate tumorigenesis in these models, with particular emphasis on pathways known to be commonly altered in human prostate carcinoma. This proposal seeks to develop an in vivo genetic model of prostate cancer that recapitulates the human disease. This will provide an important tool for studying the molecular events that lead to prostate cancer.
目前大多数前列腺癌转基因小鼠模型的缺点是起始癌基因(SV 40 T抗原)在人类疾病的发病机制中没有已知的作用。 因此,关键是要产生一种改进的前列腺癌小鼠模型,该模型是基于在人前列腺癌中通常观察到的遗传病变。 在前列腺癌细胞中观察到的两种最常见的染色体畸变包括8号染色体短臂序列的丢失和其长臂序列的获得。位于8 p21的肿瘤抑制因子的强有力候选者是Nkx3.1,一种含有同源框的蛋白质,其表达在许多前列腺肿瘤和前列腺上皮内瘤变(PIN)病变中丢失。 我们已经使用Cre/loxP介导的重组产生成年前列腺中Nkx3.1缺失的小鼠。 这些小鼠发生了侵入前PIN病变。 Myc癌基因定位于8 q24,是许多前列腺肿瘤扩增的靶点。在PIN病变、原发癌和转移瘤中,Myc的过度表达逐渐增加,表明Myc过度表达与肿瘤进展相关。有趣的是,在前列腺癌中,8 q24的增加通常伴随着8 p21的丢失,同时8 p的丢失和8 q的增加与患者预后不良相关。该提案的总体目标是产生和表征成年前列腺中Nkx3.1有条件丧失和Myc获得的小鼠。 我们假设Nkx3.1的缺失和Myc的获得之间的合作将导致PIN病变进展为浸润性癌并最终转移性疾病。 提出了以下具体目的:1)产生和表征在前列腺中Cre介导的重组后过表达Myc的转基因小鼠。 2)产生并表征前列腺中同时缺失Nkx3.1和过表达Myc的小鼠。 3)研究这些模型中前列腺肿瘤发生中改变的遗传途径,特别强调已知在人类前列腺癌中通常改变的途径。 该提案旨在开发一种重现人类疾病的前列腺癌体内遗传模型。 这将为研究导致前列腺癌的分子事件提供重要工具。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sarki A. Abdulkadir其他文献
Death ligand receptor (DLR) signaling: Its non-apoptotic functions in cancer and the consequences of DLR-directed therapies
死亡配体受体(DLR)信号传导:其在癌症中的非凋亡功能以及 DLR 定向疗法的后果
- DOI:
10.1016/j.drudis.2025.104299 - 发表时间:
2025-02-01 - 期刊:
- 影响因子:7.500
- 作者:
Khalid Rashid;Holger Kalthoff;Sarki A. Abdulkadir;Dieter Adam - 通讯作者:
Dieter Adam
PIM kinase inhibition counters resistance to radiotherapy and chemotherapy in human prostate cancer
PIM激酶抑制可对抗人类前列腺癌对放疗和化疗的耐药性
- DOI:
10.1016/j.radonc.2025.110794 - 发表时间:
2025-05-01 - 期刊:
- 影响因子:5.300
- 作者:
Anne Rajkumar-Calkins;Vinay Sagar;Jian Wang;Shania Bailey;Philip Anderson;Sarki A. Abdulkadir;Austin N. Kirschner - 通讯作者:
Austin N. Kirschner
Sarki A. Abdulkadir的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sarki A. Abdulkadir', 18)}}的其他基金
Small molecule probes of MYC stability and function intumorigenesis
MYC稳定性和肿瘤发生功能的小分子探针
- 批准号:
10570873 - 财政年份:2021
- 资助金额:
$ 24.79万 - 项目类别:
Small molecule probes of MYC stability and function intumorigenesis
MYC稳定性和肿瘤发生功能的小分子探针
- 批准号:
10361512 - 财政年份:2021
- 资助金额:
$ 24.79万 - 项目类别:
Tumor immune and glycan biomarkers for progressive prostate cancer
进展性前列腺癌的肿瘤免疫和聚糖生物标志物
- 批准号:
10305592 - 财政年份:2017
- 资助金额:
$ 24.79万 - 项目类别:
Tumor immune and glycan biomarkers for progressive prostate cancer
进展性前列腺癌的肿瘤免疫和聚糖生物标志物
- 批准号:
10053324 - 财政年份:2017
- 资助金额:
$ 24.79万 - 项目类别:
Project 1: Targeting the MYC Pathway in Prostate Cancer
项目 1:靶向前列腺癌中的 MYC 通路
- 批准号:
10089063 - 财政年份:2015
- 资助金额:
$ 24.79万 - 项目类别:
Administrative, Leadership Development and Advocacy Core
行政、领导力发展和宣传核心
- 批准号:
10089060 - 财政年份:2015
- 资助金额:
$ 24.79万 - 项目类别:
EPHB4 Receptor Kinase as a Target in Prostate Cancer
EPHB4 受体激酶作为前列腺癌的靶点
- 批准号:
8932478 - 财政年份:2015
- 资助金额:
$ 24.79万 - 项目类别:
Integrating Epigenomic and Nuclear Receptor Signaling in Castrate Resistant Prostate Cancer
整合表观基因组和核受体信号在去势抵抗性前列腺癌中的应用
- 批准号:
9103013 - 财政年份:2015
- 资助金额:
$ 24.79万 - 项目类别:
相似国自然基金
ROBO4对视网膜血管生成(angiogenesis)的调控及其分子机制
- 批准号:81200692
- 批准年份:2012
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Role of platelets for tissue remodelling - modulation of angiogenesis, inflammation and apoptosis
血小板在组织重塑中的作用 - 调节血管生成、炎症和细胞凋亡
- 批准号:
208707263 - 财政年份:2011
- 资助金额:
$ 24.79万 - 项目类别:
Clinical Research Units
Basik research of anti-angiogenesis and apoptosis targeted therapy
抗血管生成和凋亡靶向治疗的基础研究
- 批准号:
15591392 - 财政年份:2003
- 资助金额:
$ 24.79万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Role of Integrin-Mediated Apoptosis during Angiogenesis
整合素介导的细胞凋亡在血管生成过程中的作用
- 批准号:
6763040 - 财政年份:2002
- 资助金额:
$ 24.79万 - 项目类别:
Role of Integrin-Mediated Apoptosis during Angiogenesis
整合素介导的细胞凋亡在血管生成过程中的作用
- 批准号:
6616114 - 财政年份:2002
- 资助金额:
$ 24.79万 - 项目类别:
Role of Integrin-Mediated Apoptosis during Angiogenesis
整合素介导的细胞凋亡在血管生成过程中的作用
- 批准号:
7078334 - 财政年份:2002
- 资助金额:
$ 24.79万 - 项目类别:
Role of Integrin-Mediated Apoptosis during Angiogenesis
整合素介导的细胞凋亡在血管生成过程中的作用
- 批准号:
6551878 - 财政年份:2002
- 资助金额:
$ 24.79万 - 项目类别:
Mechanism of acquiring angiogenesis apoptosis in urogenital cancer
泌尿生殖癌获得血管生成凋亡的机制
- 批准号:
12470334 - 财政年份:2000
- 资助金额:
$ 24.79万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Induction of apoptosis and inhibition of angiogenesis by COX-2 inhibitors in hepatocellular carcinomas
COX-2 抑制剂在肝细胞癌中诱导细胞凋亡并抑制血管生成
- 批准号:
11670551 - 财政年份:1999
- 资助金额:
$ 24.79万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
GENOMICS OF APOPTOSIS & ANGIOGENESIS IN ISLET CARCINOMA
细胞凋亡的基因组学
- 批准号:
6376879 - 财政年份:1998
- 资助金额:
$ 24.79万 - 项目类别:
GENOMICS OF APOPTOSIS & ANGIOGENESIS IN ISLET CARCINOMA
细胞凋亡的基因组学
- 批准号:
2896602 - 财政年份:1998
- 资助金额:
$ 24.79万 - 项目类别:














{{item.name}}会员




